

## Gardasil<sup>®</sup> 9 (human papillomavirus 9-valent vaccine, recombinant) – Expanded indication

- On June 12, 2020, Merck announced the FDA approval of Gardasil 9 (human papillomavirus [HPV] 9-valent vaccine, recombinant), for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in males and females 9 through 45 years of age.
  - Previously, Gardasil 9 was approved in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
  - Previously, Gardasil 9 was approved in males 9 through 45 years of age for the prevention of anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
  - The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Gardasil 9 is also approved in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 and genital warts caused by HPV types 6 and 11.
- Gardasil 9 is approved in males 9 through 45 years of age for the prevention of anal precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 and genital warts caused by HPV types 6 and 11.
- The effectiveness of Gardasil 9 against oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, is based on the effectiveness of Gardasil and Gardasil 9 to prevent anogenital disease caused by HPV types covered by the vaccine.
- The dose of Gardasil 9 for all indications is 0.5 mL intramuscularly as follows:

Age	Regimen	Schedule
9 through 14 years	2-dose	0, 6 to 12 months*
	3-dose	0, 2, 6 months
15 through 45 years	3-dose	0, 2, 6 months

<sup>\*</sup>If the second dose is administered earlier than 5 months after the first dose, administer a third dose at least 4 months after the second dose.



## optumrx.com

 $OptumRx^{@}\ specializes\ in\ the\ delivery,\ clinical\ management\ and\ affordability\ of\ prescription\ medications\ and\ consumer\ health\ products.$  We are an  $Optum^{@}\ company\ --$  a leading provider of integrated health services. Learn more at optum.com.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.